Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery
- 1 January 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (1) , 1-14
Abstract
Objectives: The present review explores the therapeutic application of herbals in rheumatoid arthritis (RA) therapy, and how nano/submicromedicine can be fit in the scope of its therapeutic delivery in RA has been addressed. Key findings: Incorporation of bioactive such as polyphenols, thymoquinone, resveratrol, hesperidin, curcumin, celastrol and gambogic acid in a dose-dependent manner showed quite high efficacy for the treatment of RA. It can be attributed to their targeting ability against various inflammatory mediators including nitric oxide (NO), cytokines, chemokines, adhesion molecules, NF-kβ, lipoxygenase (LOXs) and arachidonic acid (AA). Despite the presence of significant merits, the use of these bioactives has several demerits such as poor bioavailability as a function of low aqueous solubility and higher first-pass metabolism upon oral administration. The impact of nano/submicromedicine in the delivery of these bioactives against RA has gained wider attention owing to bioavailability enhancement, higher stability and better efficacy. Conclusion: Phytoconstituents possess immense potential in RA pharmacotherapy, but the obstacles for their effective delivery can be overcome using nano/submicrocarrier-based drug delivery technologies, which maximize the efficacy of these herbal antirheumatic drugs without any systemic adverse effects.Keywords
This publication has 80 references indexed in Scilit:
- Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the ArtCurrent Topics in Medicinal Chemistry, 2016
- Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid ArthritisRecent Patents on Anti-Infective Drug Discovery, 2016
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnnals of the Rheumatic Diseases, 2016
- Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid ArthritisRecent Patents on Nanomedicine, 2015
- Solid Lipid Nanoparticles: A Potential Multifunctional Approach towards Rheumatoid Arthritis TheranosticsMolecules, 2015
- Interleukin‐1 Acts via the JNK‐2 Signaling Pathway to Induce Aggrecan Degradation by Human ChondrocytesArthritis & Rheumatology, 2015
- Are glucocorticoids harmful to bone in early rheumatoid arthritis?Annals of the New York Academy of Sciences, 2014
- The Immunology of Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2007
- Evolving concepts of rheumatoid arthritisNature, 2003
- Rheumatoid arthritis: Review of psychological factors related to etiology, effects, and treatment.Psychological Bulletin, 1985